acura pharma big news - 500 Beiträge pro Seite

[1bull007]

Acura Pharma (ACUR), Pfizer (PFE) Confirm FDA Approval of Oxectatm for Pain Management

More News related to ACUR
Shares of Acura Pharma (ACUR) resume trading up 70%
Shares of Acura Pharma (ACUR) to resume trading at 8am ET
Acura Pharma (ACUR), Pfizer (PFE) Confirm FDA Approval of Oxectatm for Pain Management
Pfizer and Acura Announce FDA Approval of Oxectatm (Oxycodone HCL, USP) CII
Reports Acura Pharmaceuticals (ACUR) Painkiller Approved by FDA, Shares Halted
More News related to ACUR
More News related to PFE
Acura Pharma (ACUR), Pfizer (PFE) Confirm FDA Approval of Oxectatm for Pain Management
Pfizer and Acura Announce FDA Approval of Oxectatm (Oxycodone HCL, USP) CII
Apricus Biosciences' CEO Sees Higher Revenue if Pfizer Viagra(R) Litigation is Successful
Five Prime Therapeutics Provides an Update on Its Strategic Discovery Collaborations With Pfizer and GlaxoSmithKline
pSivida (PSDV), Pfizer (PFE) Amend Latanoprost Delivery Agreement
More News related to PFE
More News related to Corporate News
Ford (F) Plans Massive Billion-Dollar Overhaul of Struggling Lincoln Brand
Office Depot (ODP) Takes Pre-Orders for H-P (HPQ) TouchPad Tablet
Asian Solar Firms Sell Assets and Lower Expansion Plans Amid Weak Demand
Boeing (BA) Gets 33 Airplane Purchase Commitment from Air Lease (AL)
Pluristem (PSTI) Unit Enters Out-License Agreement with United Therapeutics (UTHR)
More News related to Corporate News
June 20, 2011 7:32 AM EDT

Acura Pharma (Nasdaq: ACUR), Pfizer (NYSE: PFE) confirm FDA marketing approval of Oxectatm for acute and chronic moderate to severe pain management.

OXECTA is the first immediate-release oxycodone HCl medicine that applies technology designed to discourage common methods of tampering associated with opioid abuse and misuse. This AVERSION® Technology is a unique composition of commonly used pharmaceutical ingredients. Pfizer is licensing the technology in OXECTA from Acura.

"We are excited to be partnered with Pfizer to bring OXECTA to patients who need opioids to manage their pain," said Robert Jones, interim president and CEO of Acura. "Acura is focused on developing technologies that are intended to potentially deter abuse and misuse."

[1bull007]

Hier geht es gleich rund !

[1bull007]

Acura Pharmaceuticals to Present at the BioCentury NewsMakers in the Biotech Industry Conference


Acura Pharmaceuticals, Inc. (MM) (NASDAQ:ACUR)
Intraday Stock Chart

Today : Tuesday 18 October 2011

Acura Pharmaceuticals, Inc. (NASDAQ: ACUR), a specialty pharmaceutical company innovating abuse deterrent drugs, announced today that the company is scheduled to present at the 18th Annual NewsMakers in the Biotech Industry Conference at the Millennium Broadway Hotel in New York City on Friday, October 21. Bob Jones, Acura Pharmaceutical's Chief Executive Officer will provide a company overview at 3:00 PM Eastern Time.

During the presentation, material information concerning the Company, its operations, strategies and prospects may be discussed. A live webcast of the presentation will be available through the Investor page of Acura's website: www.acurapharm.com. An archived version of the presentation will be available for 30 days after the event.

Utilizing its proprietary AVERSION® and IMPEDE™ technologies, Acura develops products intended to address medication abuse and misuse. AVERSION contains polymers that cause the drug to gel when dissolved; it also contains compounds that irritate the nose.

IMPEDE is designed to disrupt the processing of pseudoephedrine from tablets into methamphetamine.

About Acura Pharmaceuticals

Acura Pharmaceuticals is a specialty pharmaceutical company engaged in the research, development and commercialization of product candidates intended to address medication abuse and misuse, utilizing its proprietary AVERSION and IMPEDE technologies. In June 2011, the U.S. Food and Drug Administration approved the first product incorporating the AVERSION technology. The Company has a development pipeline of additional AVERSION technology products including other opioids, stimulants and benzodiazepines and its IMPEDE technology for pseudoephedrine hydrochloride products

[1bull007]

Acura Pharmaceuticals Provides Update on Opioid Product Licensed to Pfizer


Acura Pharmaceuticals, Inc. (MM) (NASDAQ:ACUR)
Intraday Stock Chart

Today : Tuesday 18 October 2011

Acura Pharmaceuticals, Inc. (NASDAQ: ACUR), a specialty pharmaceutical company, announced that they have been informed by Pfizer, Inc. (NYSE: PFE) that Pfizer has commenced executing its commercialization plan for OXECTA® (oxycodone HCl, USP) Tablets CII in the United States. Acura is eligible to receive tiered royalties ranging from 5% to 25% on net sales of OXECTA. The royalties commence on the first anniversary of the first commercial sale of OXECTA which Acura does not expect to occur during 2011.

"We are excited that Pfizer is advancing the commercialization of OXECTA, a product using Acura's AVERSION® technology," said Bob Jones, chief executive officer of Acura Pharmaceuticals. "Acura is committed to maximizing our AVERSION and IMPEDE technology platforms to develop effective medications that address physician and public safety concerns about potential misuse." AVERSION contains polymers that cause the drug to gel when dissolved; it also contains compounds that irritate the nose.

Opioid medications are an important treatment option for patients with moderate to severe pain who are not adequately managed by other pain treatments. Immediate release opioid products represent the largest prescribed drug class in the United States. However, abuse and misuse of opioids is a serious public health and safety issue that is the focus of a number of recent United States government initiatives. U.S. government statistics indicate 12.4 million people used prescription pain relievers non-medically in 2009, with the vast majority of this non-medical use attributed to immediate release products.

OXECTA Important Safety Information

OXECTA is contraindicated in patients with respiratory depression in unmonitored settings and in the absence of resuscitative equipment, in any patient who has or is suspected of having paralytic ileus, in patients with acute or severe bronchial asthma or hypercarbia, and in patients with known hypersensitivity to oxycodone, oxycodone salts, or any components of the product.

Respiratory depression is the primary risk of OXECTA. This is more common in elderly or debilitated patients, in those suffering from conditions such as COPD, severe asthma, or upper airway obstruction, or following large initial doses of opioids given to non-tolerant patients.

OXECTA contains oxycodone HCl, an opioid agonist and a Schedule II controlled substance. Such drugs are sought by drug abusers and people with addictions. OXECTA can be abused in a manner similar to other opioids and narcotics. This should be considered when prescribing or dispensing oxycodone HCl in situations where the physician or pharmacist is concerned about an increased risk of misuse or abuse. OXECTA may be abused by crushing, chewing, snorting or injecting the product. These practices pose a significant risk to the abuser that could result in overdose and death. OXECTA should not be given to anyone other than the individual for whom it was prescribed. Keep OXECTA in a locked cabinet, drawer or medicine safe so that it will not be stolen.

There is no evidence that OXECTA has a reduced abuse liability compared to immediate-release oxycodone.

Take each OXECTA tablet with enough water to ensure complete swallowing immediately after placing in the mouth, and OXECTA must be swallowed whole. As OXECTA is not amenable to crushing and dissolution, do not use OXECTA in nasogastric, gastric or other feeding tubes as it may cause obstruction of feeding tubes.

Patients who have not been receiving opioid analgesics should start on OXECTA in a dosing range of 5 to 15 mg every 4 to 6 hours as needed for pain. The dose should be titrated based upon the individual patient's response to their first dose of OXECTA. Patients with chronic pain may need to be dosed at the lowest dosage level that will achieve acceptable pain relief and tolerable adverse reactions, on an around-the-clock basis rather than on an as needed basis. When a patient no longer needs treatment with OXECTA after long-term use, it is important to gradually taper OXECTA over time to prevent withdrawal symptoms.

Patients taking OXECTA in combination with other medicines like sedatives, anesthetics or narcotics may have serious problems such as respiratory depression, low blood pressure, profound sedation, or coma. Do not drink alcoholic beverages or take any medicines containing alcohol while taking OXECTA.

Use OXECTA with caution in patients with head injuries or other conditions that increase pressure in the brain, shock with low blood volume, severe undiagnosed abdominal conditions, history of seizures, severe kidney or liver disease, gall bladder disease, Addison's disease, hypothyroidism, enlarged prostate or other illnesses that make urination difficult and elderly or debilitated patients. Do not use OXECTA in patients with intestinal obstruction especially paralytic ileus.

Patients taking OXECTA should use caution when driving a car, operating heavy machinery or doing similar, potentially dangerous tasks as OXECTA may impair abilities needed to drive or perform potentially dangerous activities.

The most common adverse reactions are nausea, constipation, vomiting, headache, itchiness, trouble sleeping, dizziness, loss of strength/energy, and sleepiness.

Keep OXECTA out of the reach of children. If a child accidently takes OXECTA, seek emergency medical help immediately.

Additional information on the prescribing information for OXECTA can be found here http://www.pfizer.com/products/rx/prescription.jsp

About Acura Pharmaceuticals

Acura Pharmaceuticals is a specialty pharmaceutical company engaged in the research, development and commercialization of product candidates intended to address medication abuse and misuse, utilizing its proprietary AVERSION and IMPEDE technologies. In June 2011, the U.S. Food and Drug Administration, or FDA, approved OXECTA which incorporates the AVERSION technology. The Company has a development pipeline of additional AVERSION technology products including other opioids, stimulants and benzodiazepines and its IMPEDE technology for pseudoephedrine hydrochloride products.

Forward-Looking Statements

Certain statements in this press release constitute "forward-looking statements" within the meaning of the Private Securities Litigation Reform Act of 1995. Such forward-looking statements involve known and unknown risks, uncertainties and other factors which may cause our actual results, performance or achievements to be materially different from any future results, performance, or achievements expressed or implied by such forward-looking statements. Forward-looking statements may include, but are not limited to, the ability of Pfizer (to whom we have licensed our AVERSION® Technology for certain opioid analgesic products in the United States, Canada and Mexico) to successfully launch and commercialize such products, the ability of Pfizer and the ability of other pharmaceutical companies, if any, to whom we may license our AVERSION Technology or IMPEDE Technology, to obtain necessary regulatory approvals and commercialize products utilizing such technologies and the market acceptance of such products, expectations regarding potential market share for our products, our ability to enter into additional license agreements for our other product candidates, the ability to avoid infringement of patents, trademarks and other proprietary rights of third parties and the ability of our patents to protect our products from generic competition, and the ability to fulfill the FDA's requirements for approving our product candidates for commercial manufacturing and distribution in the United States, including, without limitation, the adequacy of the results of the laboratory and clinical studies completed to date and the results of laboratory and clinical studies we may complete in the future to support FDA approval of our product candidates, the adequacy of the development program for our product candidates, including whether additional clinical studies will be required to support FDA approval of our product candidates, changes in regulatory requirements, adverse safety findings relating to our product candidates, whether the FDA will agree with our analysis of our clinical studies and how it may evaluate the results of these studies or whether further studies of our product candidates will be required to support FDA approval, whether or when we are able to obtain FDA approval of labeling for our product candidates for the proposed indications or for abuse deterrent features, and whether our product candidates will ultimately deter abuse in commercial settings. In some cases, you can identify forward-looking statements by terms such as "may," "will," "should," "could," "would," "expects," "plans," "anticipates," "believes," "estimates," "projects," "predicts," "potential" and similar expressions intended to identify forward-looking statements. These statements reflect our current views with respect to future events and are based on assumptions and subject to risks and uncertainties. Given these uncertainties, you should not place undue reliance on these forward-looking statements. We discuss many of these risks in greater detail in our filings with the Securities and Exchange Commission.

[1bull007]

Sieht ja ganz gut aus, von den Zukunftsaussichten ganz zu schweigen.

[1bull007]

http://ih.advfn.com/p.php?pid=staticchart&volume=1&s=N%5EACU…